Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Drug Deliv Transl Res. 2014 Apr 1;4(2):203–209. doi: 10.1007/s13346-013-0190-7

Fig. 2.

Fig. 2

In vivo efficacy of IP delivered PTX/PEG-PSA microspheres, Taxol® or blank PEG-PSA microspheres in mice bearing IP MOSEC-luc tumors. (a) Bioluminescence signals from MOSEC-luc tumors. PTX/PEG-PSA particles better suppressed tumor growth than other treatments. ** indicates statistical difference between PTX/PEG-PSA and other groups starting from Day 19 (p < 0.01). (b) Kaplan-Meier survival curves. PTX/PEG-PSA particles significantly extended animal survival to > 75 days compared to blank PEG-PSA particles (34 days) and Taxol® (47 days). * indicates statistical difference between PTX/PEG-PSA and other groups (p < 0.05). (c) Representative bioluminescence images of IP tumor burden. Data represent mean ± S.E.M. (n = 5 per treatment set)